Prescient Therapeutics (ASX:PTX) locks in two licences for new cell therapy tech
Anti-cancer biotech company Prescient Therapeutics (PTX) has received two key licences to build a new...
Anti-cancer biotech company Prescient Therapeutics (PTX) has received two key licences to build a new...
It is impossible to overstate the unprecedented disruptions the world is facing with COVID-19. Stock...
AFL player Ben Brown recently shared a story about his cousin Grace’s battle with cancer,...
Cancer is the leading cause of death in Australia, claiming almost 50,000 lives in 2019....
When you think of cancer therapies, you may automatically think of chemo and radiation. While...
Personalised medicine seems to be the way of the future; where patients receive tailored treatments...
Revolution Medicines has filed to raise $100 million in an IPO. The anticipated fundraising haul will bankroll...
Cancer has been on the public radar for many years now and, although several drugs...
We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16...
Whether a day trader or a long-term investor, we often examine research released by industry...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.